Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taxoprexin in Advanced Renal Cell Carcinoma
NCT00024388Phase 2Unknown
- Sponsor
- Theradex Oncology
- Start
- Apr 2001
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of paclitaxel docosahexaenoic acid in renal cell carcinoma (RCC), sponsored by Theradex Oncology. Status: unknown.
02
Drugs
paclitaxel docosahexaenoic acid
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00024388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00024388.